Romero GA, Gil AM, Ortiz LA, Tamayo RM, Felinciano ÁV, Suárez CJC, Gutiérrez LJH

Language: Spanish
References: 25
Page: 81-88
PDF size: 138.90 Kb.

ABSTRACT

The Evans syndrome, first described in 1951, is an autoimmune disorder characterized by the simultaneous or sequential development of hemolytic anemia and immune thrombocytopenia or immune neutropenia. It may be of primary origin or secondary to other diseases or conditions such as systemic lupus erythematosus, lymphoproliferative disorders or primary immunodeficiencies. Its association with scleroderma is considered very rare. The word scleroderma, which literally means hard skin, designates a group of diseases and syndromes of common feature in induration and thickening the skin. It is characterized by the presence of excessive deposition of connective tissue components, expressed as histic fibrosis, and structural alterations of the vascular bed. With a broad clinical view, it primarily affects the skin and certain internal organs such as gastrointestinal tract, lung, heart and kidney. We present a 75 year-old female, black skin, with a history of hypertension, type 2 diabetes, ischemic heart disease and scleroderma, the latter diagnosed six months before admission. The patient referred marked weakness, pale skin and generalized petechiae. The complete blood count detected severe anemia, thrombocytopenia and reticulocytosis. Other studies showed positive direct Coombs test and severe hypercellularity. Evans Fisher syndrome was diagnosed and treated with steroids and immunomodulators; clinical improvement and hematologic remission was achieved.

REFERENCES

1. Correa González LC. Desenmascarando el síndrome de Fisher Evans. Programa educativo: Simposium anemias hemolíticas. Rev Hematología. 2010 Abr-May; 11(Supl 1):46-7.

2. Michel M, Chanet V, Dechartres A, Morin AS, Piette JC, Cirasino L, et al. The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases. Blood. 2009;114(15):3167-72.

3. Kiran Dhingra K, Jain D, Mandal S, Khurana N, Singh T, Gupta N. Evans syndrome: a study of six cases with review of literature. Hematology. 2008;13(6):356-60.

4. Jin Oh H, Jae Yun M, Tae Lee S, June Lee S, Yeon Oh S, Sohn I. Evans syndrome following long-standing Hashimoto's thyroiditis and successful treatment with rituximab. Korean J Hematol. 2011;46(4):279-82.

5. Hui C, Xin-lei J, Heng-miao G, Su-yun Q. Comorbid presentation of severe novel influenza A (H1N1) and Evans syndrome: a case report. Chin Med J. 2011;124(11):1743-6.

6. Hunzelmann N. Systemic scleroderma. Ann Rheum. 2013;64(4):299-312. doi: 10.1007/s00105-013-2537-x.

7. Seung-Woo B, Myung-Won L, Hae-Won R, Kyu-Seop L, Ik-Chan S, Hyo-Jin L, et al. Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases. Korean J Hematol. 2011;46(2):111-7. DOI:10.5045/kjh.2011.46.2.111.

8. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2005; 132:12537. doi:10.1111/j.1365-2141.2005.05809.x

9. McLeod AG, Pai M, Carter RF, Squire J, Barr RD. Familial Evans syndrome: a report of an affected sibship. J Pediatr Hematol Oncol. 1999;21:2447.

10. Mathew P, Chen G, Wang W. Evans Syndrome: results of a national survey. J Pediatr Hematol Oncol. 1997;19:4337.

11. Savasan S, Warrier I, Ravindranath Y. The spectrum of Evans' syndrome. Arch Dis Child. 1997 Sep;77:2458.

12. García-Muñoz R, Rodríguez-Otero P, Pegenaute C, Merino J, Jakes-Okampo J, Llorente L, et al. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells. Ann Hematol. 2009;88(2):177-8.

13. Hauswirth AW, Skrabs C, Schutzinger C, Raderer M, Chott A, Valent P, et al. Autoimmune thrombocytopenia in non-Hodgkin's lymphomas. Haematologica. 2008;93(3):447-50. doi:10.3324/haematol.11934.

14. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood. 2008;111(8):4029-38. doi:10.1182/blood-2007-10-119974.

15. Yi Y, Zhang GS, Gong FJ, Yang JJ. Multiple myeloma complicated by Evans syndrome. Intern Med J. 2009;39:421-2.

16. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma. 2009;50:1261-8.

17. Michel M, Chanet V, Galicier L, Ruivard M, Levy Y, Hermine O, et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of literature. Medicine. 2004;83(4):254-63.

18. Wang JY, Li JC, Zhu SX. One child with Evans syndrome. J Binzhou Med Univ (Chin) 2009;32:130.

19. Quinn P, Gilligan O.M, Horgan M. Evan's syndrome complicating multicentric Castleman's disease- dramatic response to rituximab. Eur J Haematol. 2004;73:3845.

20. Kamezaki K, Fukuda T, Makino S, Harada M. Evans' syndrome following autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Clin Lab Haematol. 2004;26:291-3.

21. Urban C, Benesch M, Sovinz P, Schwinger W, Lackner H. Fatal Evans' syndrome after matched unrelated donor transplantation for hyper-IgM syndrome. Eur J Haematol. 2004;72:444-7.

22. Schneppenheim R, Budde U, Hassenpflug W, Obser T. Severe ADAMTS-13 deficiency in childhood. Sem Hematol. 2004; 41:839.

23. Snowden JA, Martin-Rendon E, Watt SM. Clinical stem cell therapies for severe autoimmune diseases. Transfusion Medicine 2009; 19:22334. doi:10.1111/j.1365- 3148.2009.00927.x

24. Kashif M, Qureshi A , Adil SN, Khurshid M. Successful use of Rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010;60(1):64-5.

25. Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;141(2):149-69.